Cost-Effectiveness of Apremilast In Psoriatic Arthritis In Scotland.

events were considered, reflecting the year 2015. All outcomes were discounted at 3.5% annually. Results: Regarding the AS subpopulation, the total treatment cost for IFX, ADA, CZP, ETA, GOL and CC was: € 67,736, € 38,914, € 38,721, € 38,290, € 35,338 and € 4,110; and the quality-adjusted life years (QALYs) were: 10.031, 9.882, 9.949, 9.933, 9.903 and 9.360, respectively. CZP dominated ADA and it was costeffective compared to ETA generating an incremental cost-effectiveness ratio (ICER) of € 26,848/QALY gained (willingness-to-pay threshold: € 34,000). CZP was less effective (-0.082 QALYs) but less costly (-€ 29,015) than IFX, whereas it was more effective (+0.046 QALYs) and more costly (+€ 3,383) than GOL. CZP and GOL provided the lowest ICERs versus CC amongst comparators. Regarding nr-axSpA, the total treatment cost with CC, ADA and CZP was: € 4,754, € 33,748 and € 34,625; and QALYs were: 10.412, 10.681 and 10.948. The ICER of CZP versus CC and ADA was € 55,726 and € 3,289, respectively; CZP dominated ADA. ConClusions: CZP may be considered a cost-effective option with respect to the alternative axSpA therapies in Greece.